Tumoricidal methotrexate-antibody conjugate

Details Tumoricidal methotrexate-antibody conjugate Tumoricidal methotrexate-antibody conjugate

1986-02-25

1987-10-13

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Lymphokine

530391, 530809, A61K 31705, A61K 3744, C07K 1500

Patent

active

046997849

ABSTRACT:
A conjugate of methotrexate to an antibody is prepared by loading methotrexate onto an aminodextran, then specifically conjugating the polymer carrier to the carbohydrate portion of an antitumor antibody, using a reduced Schiff base linkage. The conjugate is useful for tumor targeted therapy.

REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4093607 (1978-06-01), Sela et al.
patent: 4263279 (1981-04-01), Sela et al.
patent: 4315851 (1982-02-01), Yoshikumi et al.
Int. J. Cancer, 13: 151-163 (1974), Banjo et al.
Europ. J. Cancer, 13 (1977), 593-596, Rowland.
J. Natl. Cancer Inst., 61, (1978), 657-676, Ghose et al.
Cancer Research, 41, 2700-2706, (1981), Kulkarni et al.

Affiliated with

Also associated with

Rating

Tumoricidal methotrexate-antibody conjugate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumoricidal methotrexate-antibody conjugate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumoricidal methotrexate-antibody conjugate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-410442